Dr. Krishnan Viswanadhan is a biopharmaceutical executive with over 20 years of broad cross-functional experience in advancing new medicines for patients with serious and life-threatening diseases. Krishnan joined Be Bio as president and chief operating officer, where he is responsible in driving all operational aspects of the business to unleash the power of engineered B cell medicines as therapeutics for patients with serious diseases.
Prior to Be Bio, Krishnan was senior vice president, global cell therapy franchise lead at Bristol Myers Squibb (BMS) where he was responsible for overseeing the integrated cell therapy franchise strategy across the enterprise including building core capabilities including key investments to support long term growth. He oversaw the teams responsible for the development, approval and life cycle management of Breyanzi, a CD19 CAR-T and Abecma, the first BCMA CAR T therapy.
Prior to BMS, Krishnan was vice president, business development and global alliances at Celgene Corporation responsible for managing the portfolio of partnerships and equity investments. Prior to Celgene, Krishnan had roles in large and small companies in regulatory strategy.
Krishnan is a registered pharmacist and received his Pharm.D. from Rutgers University and holds an MBA degree from Cornell University. Krishnan currently serves the board as a non-executive director of JW Therapeutics, a leading cell therapy company in China.
